The most recent years have significantly expanded knowledge regarding risks and benefits of resuming oral anticoagulation (OAC) after intracerebral hemorrhage (ICH). No randomized data is yet available, though several large observational studies and meta-analyses have investigated the impact of resuming OAC on thromboembolic versus hemorrhagic complications in these high-risk patients after ICH.
Aims
The present review will summarize the most important studies conducted over the last years and will focus on relevant factors help guiding on decision-making on whether to start OAC after ICH.
Summary of review
Several important factors (demographic, co-morbidities, clinical characteristics) need to be considered before individual decision-making for or against OAC is employed. Existing observational data suggest that patients after ICH with indication for long-term oral anticoagulation benefit from OAC given significant reductions of thromboembolic events without significantly increasing bleeding complications. Studies even suggest that thereby also clinical outcomes may be improved. Prospective trials currently recruiting patients will clarify whether OAC after ICH – or left atrial appendage closure as a meaningful alternative – is of clinical net-benefit.
Conclusions
Large sized and well-executed investigations (moderate quality of evidence) are showing that OAC resumption after ICH decreases thromboembolic complications and long-term mortality without significantly increasing bleeding complications. Further, data suggest that resumption may be safer in non-lobar ICH compared to lobar ICH, but overall, thoughtful selection, strict blood pressure control, and precise communication are paramount before starting a patient on OAC after ICH.
HemphillJC 3rdGreenbergSMAndersonCSet al.Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2015; 46: 2032–2060. .
van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 167–176.
4.
KrishnamurthiRVFeiginVLForouzanfarMHet al.Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Global Health2013; 1: e259–e281.
AurielEGreenbergSM. The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr Atheroscler Rep2012; 14: 343–350.
7.
CharidimouABoulouisGRoongpiboonsopitDet al.Cortical superficial siderosis multifocality in cerebral amyloid angiopathy: a prospective study. Neurology2017; 89: 2128–2135.
8.
OttosenTPGrijotaMHansenMLet al.Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke2016; 47: 1837–1843.
9.
NielsenPBLarsenTBSkjothFet al.Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation2015; 132: 517–525.
10.
KuramatsuJBGernerSTSchellingerPDet al.Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA2015; 313: 824–836.
11.
Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014; 9: 840–855.
12.
LipGYFrisonLHalperinJLet al.Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol2011; 57: 173–180.
13.
LipGYNieuwlaatRPistersRet al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest2010; 137: 263–272.
14.
BaileyRDHartRGBenaventeOet al.Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology2001; 56: 773–777.
15.
PoliDAntonucciEDentaliFet al.Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology2014; 82: 1020–1026.
16.
GathierCSAlgraARinkelGJet al.Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy. Cerebrovasc Dis2013; 36: 33–37.
17.
ChaoTFLiuCJLiaoJNet al.Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation2016; 133: 1540–1547.
18.
ParkYAUhmJSPakHNet al.Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm2016; 13: 1794–1802.
19.
YungDKapralMKAsllaniEet al.Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol2012; 28: 33–39.
20.
BiffiAAndersonCDBatteyTWet al.Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA2015; 314: 904–912.
21.
CharidimouAKarayiannisCSongTJet al.Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF. Neurology2017; 89: 2317–2326.
22.
MajeedAKimYKRobertsRSet al.Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke2010; 41: 2860–2866.
23.
VestergaardASSkjothFLipGYet al.Effect of anticoagulation on hospitalization costs after intracranial hemorrhage in atrial fibrillation: a registry study. Stroke2016; 47: 979–985.
24.
PennlertJOverholserRAsplundKet al.Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke2017; 48: 314–320.
25.
Chai-AdisaksophaCIorioAHillisCet al.Warfarin resumption following anticoagulant-associated intracranial hemorrhage: a systematic review and meta-analysis. Thromb Res2017; 160: 97–104.
26.
ZhouZYuJCarcelCet al.Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open2018; 8: e019672.
27.
KorompokiEFilippidisFTNielsenPBet al.Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology2017; 89: 687–696.
28.
MurthySBGuptaAMerklerAEet al.Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke2017; 48: 1594–1600.
29.
BiffiAKuramatsuJBLeasureAet al.Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol2017; 82: 755–765.
30.
HawrylukGWAustinJWFurlanJCet al.Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost2010; 8: 1500–1508.
31.
Katsanos AH, Schellinger PD, Kohrmann M, et al. Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis. Eur J Neurol 2018; 25: 1299–1302.
32.
ChatterjeeSSardarPBiondi-ZoccaiGet al.New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol2013; 70: 1486–1490.
33.
InoharaTXianYLiangLet al.Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA2018; 319: 463–473.
34.
GernerSTKuramatsuJBSembillJAet al.Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol2018; 83: 186–196.
35.
TsivgoulisGLioutasVAVarelasPet al.Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage. Neurology2017; 89: 1142–1151.
36.
WolfeZKhanSUNasirFet al.A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost2018; 16: 1296–1306.
37.
VahanianAet al.Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J2012; 33: 2451–2496.
38.
NishimuraRAOttoCMBonowROet al.2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2017; 135: e1159–e1195.
39.
HalvorsenSStoreyRFRoccaBet al.Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J2017; 38: 1455–1462.
40.
KuramatsuJBSembillJAGernerSTet al.Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J2018; 39: 1709–1723.
41.
RodriguesMASamarasekeraNLerpiniereCet al.The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol2018; 17: 232–240.
42.
van EttenESGurolMEvan der GrondJet al.Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology2016; 87: 1482–1487.
43.
CharidimouAImaizumiTMoulinSet al.Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis. Neurology2017; 89: 820–829.
44.
WilsonDAmblerGShakeshaftCet al.Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol2018; 17: 539–547.
45.
CharidimouABoulouisGXiongLet al.Cortical superficial siderosis and first-ever cerebral hemorrhage in cerebral amyloid angiopathy. Neurology2017; 88: 1607–1614.
46.
HolmesDRReddyVYTuriZGet al.Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet (London, England)2009; 374: 534–542.
47.
KirchhofPBenussiSKotechaDet al.2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J2016; 37: 2893–2962.
48.
HolmesDR JrKarSPriceMJet al.Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol2014; 64: 1–12.
49.
Nielsen-KudskJEJohnsenSPWesterPet al.Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention2017; 13: 371–378.
